<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by CREADD Ventures on Medium]]></title>
        <description><![CDATA[Stories by CREADD Ventures on Medium]]></description>
        <link>https://medium.com/@comms_52827?source=rss-0851328b5e97------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*9kSc2GDsQdcAerwV0RTAow.png</url>
            <title>Stories by CREADD Ventures on Medium</title>
            <link>https://medium.com/@comms_52827?source=rss-0851328b5e97------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Mon, 16 Nov 2026 20:33:36 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@comms_52827/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[The Swiss Venture Capital Paradox: Why Deep Tech Needs Company Builders, Not Just Check-Writers]]></title>
            <link>https://medium.com/@comms_52827/the-swiss-venture-capital-paradox-why-deep-tech-needs-company-builders-not-just-check-writers-bde98c6a5a37?source=rss-0851328b5e97------2</link>
            <guid isPermaLink="false">https://medium.com/p/bde98c6a5a37</guid>
            <category><![CDATA[switzerland]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[company-builder]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[CREADD Ventures]]></dc:creator>
            <pubDate>Wed, 04 Mar 2026 06:31:01 GMT</pubDate>
            <atom:updated>2026-03-04T06:31:01.143Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*O04gAzRyD_EZ6c57WhuTUg.jpeg" /></figure><p>Let’s stop repeating the tired narrative that Switzerland struggles with early-stage innovation. We don’t. Between the spinout engines of ETH Zurich and EPFL, the front end of our startup pipeline is arguably the most efficient in Europe. Early-stage venture investment in Switzerland just hit a record in 2025.</p><p>The <em>real</em> Swiss Valley of Death doesn’t happen in the lab. It happens at the growth stage. It hits exactly when a brilliant deep tech or biotech company needs a CHF 30 million Series B to scale manufacturing, navigate complex regulatory approvals, or build an international B2B sales engine.</p><p>According to the latest Swiss Venture Capital Report, a staggering <strong>85% of all growth-stage capital</strong> raised by Swiss startups comes from international investors. Because local founders are starved for domestic growth capital, they are backed into a corner: they either relocate their headquarters to the US, or they sell out to foreign buyers way too early.</p><p>But the crisis isn’t just about <em>where</em> the money comes from. It’s about <em>who</em> is managing it.</p><h4><strong>The Flaw of the “Passive Financier”</strong></h4><p>When a traditional mega-fund or a legacy financial institution writes a growth-stage check, they are often playing the role of a passive asset gatherer. They bring capital, a board member who looks at spreadsheets once a quarter, and a mandate to wait for an exit.</p><p>But deeptech and biotech scale-up companies don’t just need cash. They need execution.</p><p>Scaling a robotics company or a med-tech platform is fundamentally different from scaling a consumer app. The bottlenecks are highly operational: industrializing supply chains, securing international regulatory certifications, negotiating with entrenched enterprise procurement teams, hiring specialized engineering talent and developing marketing strategies that are very often strongly technical and clinically grounded. A traditional finance guy with a background in investment banking cannot help a founder cross this chasm.</p><h4><strong>The Case for the “Company Builder” Fund</strong></h4><p>If Switzerland wants to bridge the Growth Stage Valley of Death, capital must flow to a specific breed of investor: <strong>the emerging, operator-led “company builder” fund.</strong> These are venture funds professionally managed by people who have actually been in the trenches before. They are former founders, engineers, and operators who have built businesses, failed, pivoted, and scaled. Just like Creadd’s founders.</p><p>The data proves that this model works. According to a comprehensive white paper by the <strong>Colibrí Institute</strong> (featured in the <em>Venture Capital Journal</em>), which analyzed nearly 2,500 VC funds, emerging managers consistently crush their established peers — outperforming them by an average of <strong>7.2 percentage points in Internal Rate of Return (IRR)</strong> and <strong>0.34x in Total Value to Paid-In Capital (TVPI)</strong>.</p><p>Furthermore, having dedicated operational support isn’t just a nice-to-have; it’s a financial driver. Research by the <strong>VC Platform Global Community</strong> shows that venture funds with significant post-investment operational platforms outperform purely financial funds by <strong>1,100 basis points in Net IRR</strong>.</p><p>A company-builder fund doesn’t just ask for a board seat; they embed themselves in the startup. They share centralized resources, help poach top-tier talent, and leverage their own operational battle scars to help founders avoid the million-dollar mistakes that kill companies at the Series B stage.</p><h4>The Strategic Opportunity for Institutional Capital</h4><p>This shift in the investment landscape presents a natural opening for one of Switzerland’s greatest economic strengths: its institutional pension sector. With over <strong>CHF 1.1 trillion</strong> in assets under management, Swiss pension funds are the backbone of the nation’s long-term financial security. While these funds have historically prioritized capital preservation through traditional asset classes, there is a burgeoning alignment between their need for long-term, inflation-protected returns and the growth trajectory of the domestic deep-tech sector.</p><p>Recent data suggests that the risk-reward profile of Swiss venture capital has matured significantly. A landmark <strong>2025 study by the University of Basel and SECA</strong> audited cash-flow data from Swiss VC funds (2014–2020 vintages), revealing a stable average annual <strong>IRR of 14% and a 1.5x TVPI</strong>. For an institutional portfolio, a modest allocation of <strong>1% to 3%</strong> to venture capital does more than just chase yield; from a Modern Portfolio Theory perspective, it serves as a vital diversifier. By branching beyond the Swiss Performance Index (SPI) — where a handful of legacy companies drive the majority of market movement — pension funds can mitigate concentration risk while gaining exposure to the high-growth “champions of tomorrow.”</p><p>Unlocking this capital is about more than just liquidity; it is about creating a <strong>sovereign circle of prosperity</strong>. When institutional capital is deployed through specialized, operator-led funds, it ensures that Switzerland’s most promising innovations remain anchored locally. This doesn’t just protect the retirement savings of Swiss citizens; it reinvests them into the very ecosystem that generates local jobs, industrial resilience, and the technological sovereignty of the nation.</p><h4>Owning the Future</h4><p>To build global champions that remain anchored in Switzerland, capital needs to flow efficiently to where the bottlenecks are. This requires backing specialized, operator-led funds. Instead of passive financiers, the ecosystem needs investors who bring the hands-on experience required to help deep tech founders navigate the complex realities of scaling hardware and building industrial supply chains.</p><p>We don’t just need more <em>liquidity</em> in the market; we need capital that comes with <strong><em>operational</em></strong> <strong><em>expertise</em></strong>. Until that alignment happens, we will continue to invent the future, but we will never fully own it.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=bde98c6a5a37" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The VC Inside Story: How to Choose “the One”?]]></title>
            <link>https://medium.com/@comms_52827/the-vc-inside-story-how-to-choose-the-one-ce560ca59eea?source=rss-0851328b5e97------2</link>
            <guid isPermaLink="false">https://medium.com/p/ce560ca59eea</guid>
            <category><![CDATA[investment]]></category>
            <category><![CDATA[deeptech]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[ai]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[CREADD Ventures]]></dc:creator>
            <pubDate>Mon, 24 Nov 2025 13:56:11 GMT</pubDate>
            <atom:updated>2025-11-24T13:56:11.524Z</atom:updated>
            <content:encoded><![CDATA[<h3>Episode 3 · Industry Knowledge — The Edge You Can’t Fake</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*JJUXx_ONnUgDyJ7cjV4ghw.png" /></figure><p><strong>CREADD Ventures<br></strong>4 min read ·</p><h3>When DeepTech Demands Deep Understanding</h3><p>Every startup story begins with a pitch. But in DeepTech, the real opportunity often hides behind the engineering.<br>Recognizing it requires investors who understand the science as well as the spreadsheets.<br>That’s where domain knowledge becomes the decisive edge.</p><h3>The Delvitech Journey: From Prototype to Global Scale</h3><p>When <strong>TiVentures</strong> first met <strong>Delvitech</strong> in 2018, the founder <strong>Roberto Gatti</strong> had a bold vision: to reinvent optical inspection through a <strong>3D AI-native hardware-software platform</strong> for the electronics manufacturing industry, a sector he knew very well with his extensive experience.</p><p>TiVentures believed in his dream, trusted his competence in the industry and became the first institutional investor, hosting the company in its offices during the earliest months.<br>Our Managing Partner <strong>Paolo Orsatti</strong> worked closely with founder <strong>Roberto </strong>to develop the technical roadmap, guide early hires, and establish critical partnerships with academic and industrial partners.</p><p>TiVentures introduced a <strong>multifamily office and private investors</strong> and in 2020 facilitated the financing round led by <strong>Credit Suisse Entrepreneur Capital (CSEC), </strong>advised by <strong>Helvetica Capital</strong>.</p><h3>From Technical Validation to Venture Scale</h3><p>By 2024, Delvitech had matured from an R&amp;D-driven startup into a company ready to scale. That’s when <strong>Creadd Ventures</strong> entered, leading another round together with new private investors and existing shareholders — the bridge toward a larger global growth phase.<br><strong>Paolo Orsatti</strong> supported the company’s next leap, leveraging his expertise in <strong>semiconductors, AI, and industrial strategy</strong> to prepare Delvitech for an international expansion and its landmark financing round.</p><h3>The USD 40 Million Milestone</h3><p>In 2025, <strong>Delvitech announced the successful close of a USD 40 million Series B round</strong>, <strong>led by EGS Beteiligungen (EGSB)</strong> together with <strong>Creadd Ventures</strong>, and joined by several prominent European private investors.<br>The oversubscribed round validates strong confidence in Delvitech’s technology and marks one of Switzerland’s largest recent financings in industrial AI.</p><p>The company is now scaling globally, reinforcing its presence in <strong>Germany, India, the U.S., and Italy</strong>, with plans to open a <strong>new manufacturing plant in India in 2026</strong>.<br>Delvitech’s <strong>AI-native Automated Optical Inspection platform</strong> merges proprietary neural networks with patented Swiss-made hardware — turning inspection into <strong>intelligent prediction</strong>.<br>Instead of merely detecting errors, the system anticipates them, redefining quality control for the <strong>electronics, automotive, defense, and high-performance computing</strong> industries.</p><p>The company expects <strong>400 % sales growth by the end of 2025</strong>, underscoring the scalability of its model even in a challenging macroeconomic environment.<br>The appointment of <strong>Prof. Jürgen Schmidhuber</strong>, a pioneer of neural networks, to the <strong>Board of Directors</strong> further reinforces its scientific leadership.</p><h3>When Knowledge Becomes Capital</h3><p>Recognizing Delvitech’s potential required more than financial intuition.<br>It demanded fluency in <strong>AI algorithms, hardware integration, and industrial scaling</strong> — the kind of insight that comes only from decades of operating and investing in the field.</p><p>This depth of understanding allows Creadd Ventures to:</p><ul><li>Detect breakthrough technologies before competitors do.</li><li>Anticipate scaling challenges in manufacturing and supply chains.</li><li>Connect technical founders with global strategic partners and co-investors.</li></ul><p>As Paolo Orsatti notes, <em>“Delvitech is a perfect example of Creadd Ventures investment philosophy, based on selecting companies with solid and unique background, in this case a very extensive understanding of the market dynamics brought by Roberto Gatti. Our scientific and industrial knowledge and extensive academic network allowed Delvitech to access the talent it needed to build the technology platform and the products that are now commercialized worldwide”. You can’t invest and fully support what you don’t understand. </em>This principle defines every investment decision of Creadd Ventures.</p><h3>Founder’s Perspective</h3><p>“Creadd and TiVentures understood our vision from day one — not just the business plan. Their technical and strategic support helped us move from concept to a global industrial company.”<br> — <em>Roberto Gatti, Founder &amp; CEO of Delvitech</em></p><h3>The Takeaway</h3><p>Capital launches the journey.<br><strong>Expertise and hands-on support keeps it on course.</strong></p><p>For founders, choosing a VC with real industry depth can turn an ambitious prototype into a category-defining company.<br>For LPs, it’s the clearest sign that “value-add” isn’t marketing — it’s mastery.</p><p><strong>Follow Creadd Ventures<br></strong>https://creadd.ch | <a href="https://www.linkedin.com/company/creadd-ventures/">LinkedIn</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ce560ca59eea" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Focus Portfolio — The Aesyra Story]]></title>
            <link>https://medium.com/@comms_52827/focus-portfolio-the-aesyra-story-088dc3af5067?source=rss-0851328b5e97------2</link>
            <guid isPermaLink="false">https://medium.com/p/088dc3af5067</guid>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[switzerland]]></category>
            <category><![CDATA[deeptech]]></category>
            <dc:creator><![CDATA[CREADD Ventures]]></dc:creator>
            <pubDate>Thu, 23 Oct 2025 05:02:41 GMT</pubDate>
            <atom:updated>2025-10-23T05:02:41.587Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*FM1qGHZT3zHDPvB4g89COQ.png" /></figure><h3><strong>Focus Portfolio — The Aesyra Story</strong></h3><p><em>Turning Swiss Deeptech into better sleep for millions.</em></p><h3>From EPFL Labs to the Future of Sleep Health</h3><p>In 2019, two young engineers from <strong>EPFL</strong> — one of the world’s leading technical universities in Lausanne, Switzerland — approached us with an idea that immediately stood out.<br>They had developed and patented a <strong>novel sensor technology</strong> designed for medical applications. Their early prototype showed remarkable potential in addressing a surprisingly common yet under-diagnosed condition: <strong>sleep bruxism</strong>.</p><p><em>“It wasn’t just the technology — it was their clarity about the medical problem they wanted to solve.”</em></p><h3>The Vision</h3><p><strong>Founded:</strong> 2018 | <strong>Headquarters:</strong> Lausanne, Switzerland<br><strong>Sector:</strong> Precision Medicine · Smart Medical Devices<br><strong>Product:</strong> <em>AesyBite™ Active</em> — the world’s first oral device that monitors and treats sleep bruxism<br><strong>Status:</strong> Available in Europe · FDA registration ongoing</p><p>Bruxism — the unconscious clenching or grinding of teeth during sleep — affects up to <strong>30 % of adults</strong>.<br>It can cause disturbed sleep, headaches, jaw pain, and dental damage.</p><p>Aesyra’s solution, <strong>AesyBite™ Active</strong>, is a smart, wearable dental appliance that <strong>monitors</strong> the condition in real time and <strong>reduces it actively</strong> through intelligent biofeedback.<br>Paired with an intuitive mobile app, it empowers users to take control of their sleep health — directly from their bedside.</p><h3>Engineering Meets Medicine</h3><p>Aesyra’s mission is to <strong>develop, manufacture, and commercialize</strong> medical devices that accurately monitor and treat sleep-related diseases.</p><p>What impressed us from the beginning was not only the technology, but also the <strong>founders’ ability to bridge engineering and medicine</strong>.<br>Marco and Pietro had already established strong relationships with leading clinicians and opinion leaders.<br>This rare combination of technical mastery and clinical insight is what differentiates great Deeptech founders — they focus on solving real medical needs, not just demonstrating technological capability.</p><h3>Creadd’s Journey with Aesyra</h3><p>Our first investment came in <strong>2019</strong>, through an investment vehicle created with a group of private investors.<br><strong>Paolo Orsatti</strong>, Managing Partner at Creadd Ventures, joined the <strong>Board of Directors</strong> to provide hands-on support through Aesyra’s formative years.</p><p>Between 2020 and 2022, the company refined its sensor platform and finalized <strong>AesyBite™ Active</strong>.<br>In <strong>2023</strong>, we invested again with <strong>Creadd Ventures</strong>, joining a <strong>$3 million round</strong> alongside <strong>Supermoon Capital</strong> — a Silicon Valley VC focused on the “sleep economy” — and <strong>Zürcher Kantonalbank</strong>.</p><p><em>“This round marked a turning point — bringing together Swiss precision engineering and global market reach.”</em></p><h3>Building Momentum</h3><p>Over the past two years, Aesyra has validated its technology and business model with major milestones:</p><p>✅ <strong>Completed recruitment for their second clinical trial</strong>, a key step toward FDA registration.<strong><br></strong>✅ <strong>Expanded patent portfolio</strong>, now covering multiple medical applications<br>✅ <strong>Formed co-development partnerships</strong> with global dental leaders<br>✅ <strong>Exploring new indications</strong>, including sleep apnea and sports recovery</p><p>These achievements not only strengthen Aesyra’s IP moat, but also pave the way for global commercialization.</p><h3>Why We Believe in Aesyra</h3><p>At Creadd Ventures, Aesyra represents what Swiss Deeptech does best — combining <strong>microelectronic excellence</strong>, <strong>medical insight</strong>, and <strong>a clear go-to-market strategy</strong>.</p><p>The company’s trajectory also illustrates the <strong>three-phase value path</strong> of a Swiss Deeptech startup:</p><ol><li><strong>Seed Phase</strong> — Private investors de-risk technology and secure intellectual property.</li><li><strong>Scale-Up Phase</strong> — Professional VCs like Creadd Ventures help consolidate operations, regulatory strategy, and manufacturing.</li><li><strong>Growth Phase</strong> — Commercial expansion and entry into global markets.</li></ol><p>We expect Aesyra to emerge as the <strong>world leader in precision medicine for oral and sleep health</strong>.<br>The team’s dedication, technical depth, and clinical focus make them the kind of founders we love to back — those who turn breakthrough science into tangible health benefits.</p><h3>A Symbol of Swiss Deeptech Excellence</h3><p>Aesyra is more than a MedTech startup — it’s a <strong>testament to how Switzerland’s universities translate science into real-world impact</strong>.<br>By merging advanced micro-sensor technology with medical insight, Aesyra is redefining how we monitor and improve sleep.</p><p><em>“Converting high-tech into value means transforming brilliant research into life-changing solutions.”<br></em> — <strong>Creadd Ventures</strong></p><h3>🚀 Follow the Journey</h3><p>Learn more about <a href="https://www.aesyra.com/">Aesyra</a> and stay tuned for the next chapter of the <strong>Creadd Focus Portfolio</strong> by following us on <a href="https://ch.linkedin.com/company/creadd-ventures">LinkedIn</a>— where we spotlight the innovators shaping tomorrow’s industries.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=088dc3af5067" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The VC Inside Story: How to Choose “the One”?]]></title>
            <link>https://medium.com/@comms_52827/the-vc-inside-story-how-to-choose-the-one-206755f06c5a?source=rss-0851328b5e97------2</link>
            <guid isPermaLink="false">https://medium.com/p/206755f06c5a</guid>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[vc]]></category>
            <category><![CDATA[lp]]></category>
            <category><![CDATA[private-equity]]></category>
            <category><![CDATA[company-building]]></category>
            <dc:creator><![CDATA[CREADD Ventures]]></dc:creator>
            <pubDate>Tue, 16 Sep 2025 20:23:53 GMT</pubDate>
            <atom:updated>2025-09-16T20:23:53.626Z</atom:updated>
            <content:encoded><![CDATA[<h3>Episode 2: Experience -The Real Work Begins After the Deal-</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zKnl-eBInU8R7266tdy7-g.png" /></figure><p>When people talk about venture capital, the common misconception is that selecting the right company is mostly a matter of luck or timing. In reality, what truly matters is experience, network, and domain knowledge.</p><h3>A Case in Point</h3><p>In 2018, one of our good friends approached us about a technology developed in a biotech company in Barcelona. It was no longer a core asset and could have been available for licensing.</p><p>We paid attention.</p><p><a href="https://www.linkedin.com/in/leonilorenzo/"><strong>Lorenzo Leoni</strong></a>, Creadd co-founder and Managing Partner, had already founded and run <a href="https://tiventures.ch/"><strong>TiVentures</strong></a> and brought more than 20 years of drug development expertise. He rapidly assessed the potential of the technology and the results already obtained, identified the development strategy and points of differentiation, evaluated the quality of the existing team, and proposed the investment through TiVentures.</p><p>Before completing the initial pre-seed investment, TiVentures negotiated the license, established <a href="https://gaintherapeutics.com/"><strong>Gain Therapeutics</strong></a> in Lugano (Switzerland), and created a subsidiary in Spain to rehire the entire original team. From that moment forward, Lorenzo joined the Board of the company and actively participated in its growth.</p><p>That support was critical across three major challenges:</p><ul><li><strong>Building the team</strong>: assembling the right mix of drug development, regulatory, and strategic expertise, made possible through the network Lorenzo had developed in prior biotech ventures.</li><li><strong>Securing co-investors</strong>: bringing in the right partners to finance Gain’s growth, again achieved through long-standing connections in the venture capital community.</li><li><strong>Accessing U.S. capital markets</strong>: seizing favorable conditions to pursue a NASDAQ listing, which required identifying the right U.S. partners across finance, legal, and banking. Here, too, prior relationships proved decisive in ensuring each step was executed correctly.</li></ul><p>That sustained involvement proved decisive: in March 2021, Gain Therapeutics successfully completed an <strong>IPO on NASDAQ</strong>, raising more than $40 million to support pre-clinical and clinical development activities. For TiVentures, the multiple on the initial pre-seed investment at the time of IPO was greater than <strong>35x</strong>. Today, GANX is completing its second clinical trial for GT-02287, a best-in-class small molecule for the treatment of Parkinson’s disease and other neurodegenerative conditions.</p><h3>What LPs Should Really Look At</h3><p>When LPs are evaluating a venture capital fund, they should assess more than just deal flow. The key question is whether the Managing Partners have the capacity not only to select the right project, but also to chart and support a path that creates real value for both the company and the investors.</p><p>Prior entrepreneurial expertise is one of the strongest signals of that capacity. It often determines whether a VC can truly add value and increase the probability of success. By contrast, VCs with only a financial background often lack the skills needed to unlock the full potential of deeptech companies — and as a result, they struggle to deliver meaningful returns to LPs.</p><p>Follow <a href="https://www.linkedin.com/company/creadd-ventures"><strong>Creadd Ventures on LinkedIn</strong></a> and check out <a href="https://creadd.ch/"><strong>our website</strong></a> to read upcoming episodes.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=206755f06c5a" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The VC Inside Story: How to Choose One?]]></title>
            <link>https://medium.com/@comms_52827/the-vc-inside-story-how-to-choose-one-527085901571?source=rss-0851328b5e97------2</link>
            <guid isPermaLink="false">https://medium.com/p/527085901571</guid>
            <category><![CDATA[limited-partner]]></category>
            <category><![CDATA[investing]]></category>
            <category><![CDATA[company-building]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[startup]]></category>
            <dc:creator><![CDATA[CREADD Ventures]]></dc:creator>
            <pubDate>Tue, 02 Sep 2025 12:25:54 GMT</pubDate>
            <atom:updated>2025-09-16T20:14:47.513Z</atom:updated>
            <content:encoded><![CDATA[<h3><em>The VC Inside Story: How to Choose “the One”?</em></h3><h4><em>Beyond Capital — How Hands-On VCs Become True Company Builders</em></h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fTuwhV5Ok9Qoqy1ap4haBQ.png" /></figure><h3>The VC Myth: “Capital Is Abundant. What’s Scarce? A VC Who Actually Helps After the Wire Transfer.”</h3><p>It’s a line that gets tossed around in pitch meetings, whispered at founder dinners, and plastered across Medium posts. But the scary part? It’s not just a myth — it’s a hard truth too many startups (and their LPs) learn the moment the champagne goes flat.</p><p>Because money alone doesn’t scale companies. If it did, every fund with dry powder would deliver outsized returns. They don’t. The real test begins after the wire transfer — when promised support often fades, board meetings turn into box-checking, and founders are left flying solo at the exact moment risks peak.</p><p>That’s why, since our first investment in <strong>Aesyra in 2019</strong>, we didn’t just provide capital — we co-built the company with the founders. The result? <strong><em>A leading company in the precision medicine field, with outstanding clinical data ready for approval of their first product by FDA and for a global market launch.</em></strong></p><p>This is what “beyond capital” really means — and why it matters for performance.</p><h3>What Real Support Looks Like — And Why It Matters</h3><p>At Creadd Ventures, we believe a VC earns their seat at the table <strong>after</strong> the term sheet is signed.</p><ul><li><strong><em>Critical decision-making</em></strong><em>: We sit in the messy middle of hard calls — pivot or stay the course? Expand or consolidate? → avoids wasted capital on wrong turns.</em></li><li><strong><em>Internal structure</em></strong><em>: Building governance and scalable systems → prevents chaotic growth that destroys value.</em></li><li><strong><em>Hiring right, not just fast</em></strong><em>: From product leads to CFOs → reduces leadership churn that delays exits.</em></li><li><strong><em>Global network access</em></strong><em>: Advisors, customers, future co-investors beyond the usual circles → accelerates market entry and de-risks expansion.</em></li><li><strong><em>Timeline discipline</em></strong><em>: Challenging delivery schedules → drives velocity without burning through cash.</em></li><li><strong><em>Financial forecasting &amp; modeling</em></strong><em>: Scenario planning with eyes on the exit → protects downside while capturing upside.</em></li><li><strong><em>Market insight &amp; competitive intelligence</em></strong><em>: Helping founders see around corners → positions the portfolio to outmaneuver incumbents before it’s too late.</em></li><li><strong><em>Board dynamics &amp; investor relations</em></strong><em>: Balancing short-term noise against long-term strategy → keeps companies aligned for growth and liquidity events.</em></li></ul><p>These are the real levers of startup growth — especially at the <strong>early growth stage</strong>, where the risks are high, the decisions are pivotal, and the “support” many traditional VCs promise rarely materializes.</p><h3>Case in Point: How Aesyra Scaled Beyond the Capital</h3><p>When the founders of Aesyra approached us, they were a young spinoff company of the prestigious EPFL school in Lausanne Switzerland. They were looking for the first institutional investor to close the first financing, but they didn’t just need capital — they needed to build and growth a company.</p><p>Their technology was strong, and partially derisked. But the road was still long to create a real product, confirm the clinical evidence, develop the required regulatory framework and establish the needed industrial and commercial partnerships,</p><p>That’s where we came in.</p><p>Initially in 2019 Paolo entered the Board of Directors to supply his expertise in microelectronics, manufacturing, supply chain, and software development. He worked side-by-side with the founders to restructure leadership responsibilities, identify operational blind spots, and, critically, <strong>hire the right team to scale</strong>. In 2023, Creadd Ventures helped find an international co-investor from the bay area to lead the next round of financing and move the company close to market approval and commercialization phase. At that time, Lorenzo took Paolo’s position in the Board, to provide his clinical, regulatory and strategy business development expertise.</p><p>We helped them map an international expansion plan and provided access to our network to guide execution. It wasn’t about micromanagement — it was about really supporting the team so they could move faster and smarter.</p><p>Marco Letizia, founder and CEO od Aesyra is very clear::</p><p><strong><em>“Paolo and Lorenzo support went beyond capital — they helped us making the right choices that took us from an academic spinoff to a strong company ready to scale on the international markets.”</em></strong></p><p>No playbook fits every startup, but there should be a playbook. And ours is designed for moments like this.</p><h3>What LPs Should Be Asking</h3><p>If you’re a limited partner allocating a venture, you’ve probably heard your GPs talk about “value-add.” Here’s how to know if it’s real:</p><ul><li><strong>Ask the hard question</strong>: How do you support founders beyond capital?</li><li><strong>Push for proof</strong>: Can portfolio founders speak to specific interventions? Are there examples of board-level impact or strategic shifts?</li><li><strong>Look for repeatable systems</strong>: Do they have a framework for hiring support? For market intelligence? Or is it just promises of “being helpful”?</li></ul><p>The difference between average returns and breakout winners often comes down to this: Did the VC show up when the founders needed them most?</p><p>Because the truth is — founders remember.</p><p>And so should investors.</p><h3>Capital Starts the Journey. Support Finishes It.</h3><p>A funding round might launch a startup. But it’s the post-investment partnership that determines how far — and how fast — it goes.</p><p>At Creadd Ventures, we believe capital is just the beginning. Our edge comes in the trenches, not the press releases.</p><p>In the next post, we’ll go deeper into the pitfalls of generalist investors — and why domain-specific knowledge is often the difference between catching market signals early… or missing them entirely.</p><p>Stay tuned here:</p><p><a href="https://creadd.ch/"><em>Creadd Ventures Website</em></a><em><br></em><a href="https://www.linkedin.com/company/creadd-ventures"><em>LinkedIn</em></a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=527085901571" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>